🔗 Share this article

While America undertakes historic changes to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines during the pandemic and has focused upon potential deaths following COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Pediatric Vaccine Program

Health officials had intended to reveal radical revisions to the pediatric immunization program in December, synchronizing the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US out of alignment with a large portion of the global community with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a greater focus upon rolling back already-approved vaccines at the FDA.

Høeg has frequently advocated for discontinuing specific childhood vaccine recommendations in the US in order to be more in line with Denmark, a country with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Background

Høeg has no obvious background in pharmaceutical research, regulation or leadership, which has been standard for previous leaders of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of the center would “understand laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who ran the center have had.”

The drug center has an enormous range of responsibilities at the FDA, she emphasized.

“Many people just pays attention on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and other areas, and all of those must be managed,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the role, which manages more than 5,000 personnel. “It is a massive management job, if you perform it correctly,” she said.

Agency Reaction and Controversial Initiatives

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies increased cooperation among agency officials on vaccines, a representative said that the “concerns are based on inaccurate premises”.

“This background matches the duties of her role,” the representative said, pointing to the time Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's controversial fast-track approval initiative, a disputed rapid drug-approval program that apparently concerned her former heads. “How are these therapies being picked for this expedited pathway? Who takes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards more relaxed regulations of all drugs, with the exception of vaccines.”

Public Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, critics said. She released a analysis using unconfirmed crowd-sourced reports to assess the frequency of heart inflammation after COVID-19 immunization. She advised the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership featured changing rules for new vaccines and discontinuing “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly floated the idea of preventing adolescent males from receiving Covid vaccines.

“She’s an complete dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the data in a very disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Push for Payback”

Høeg became part of other dissenters, {like|